<PAGE>
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For The Quarterly Period Ended October 29, 1998
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For The Transition Period from . . . . . . . . to . . . . . . . .
Commission file number 1-8978
LONGS DRUG STORES CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Maryland 68-0048627
-------------------------------------------- -----------------------
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
141 North Civic Drive
Walnut Creek, California 94596
-------------------------------------------- -----------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number, including area code: (925) 937-1170
--------------
- --------------------------------------------------------------------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
----- -----
There were 38,947,293 shares of common stock outstanding as of November 26,
1998.
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
- --------------------------------------------------------------------------------
STATEMENTS OF CONSOLIDATED INCOME (UNAUDITED)
<TABLE>
<CAPTION>
For the For the Three
Quarter Ended Quarters Ended
OCTOBER 29, October 30, OCTOBER 29, October 30,
1998 1997 1998 1997
----------- ----------- ----------- -----------
----------------(Thousands Except Per Share)---------------
<S> <C> <C> <C> <C>
SALES $808,285 $714,597 $2,347,879 $2,143,797
COSTS AND EXPENSES:
Cost of merchandise sold 594,529 524,988 1,721,053 1,575,343
Operating and administrative 195,215 172,891 560,470 508,254
Net interest expense 557 223 532 360
-------- -------- ---------- ----------
INCOME BEFORE TAXES ON INCOME 17,984 16,495 65,824 59,840
TAXES ON INCOME 7,000 6,500 25,800 23,500
-------- -------- ---------- ----------
NET INCOME $ 10,984 $ 9,995 $ 40,024 $ 36,340
-------- -------- ---------- ----------
-------- -------- ---------- ----------
PER COMMON SHARE:
NET INCOME BASIC $ .28 $ .26 $ 1.04 $ .94
NET INCOME DILUTED $ .28 $ .26 $ 1.03 $ .94
DIVIDENDS $ .14 $ .14 $ .42 $ .42
WEIGHTED AVERAGE NUMBER
OF SHARES OUTSTANDING:
BASIC 38,546 38,430 38,515 38,677
DILUTED 38,728 38,591 38,692 38,842
</TABLE>
See NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.
- 1 -
<PAGE>
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
<TABLE>
<CAPTION>
OCTOBER 29, October 30, January 29,
1998 1997 1998
----------- ----------- -----------
----------------(Thousands)----------------
<S> <C> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and equivalents $ 18,479 $ 14,934 $ 48,552
Pharmacy and other receivables 64,063 59,375 63,107
Merchandise inventories 386,796 361,629 345,082
Deferred income taxes 25,895 20,601 23,244
Other 1,831 990 1,337
---------- -------- --------
Total current assets 497,064 457,529 481,322
---------- -------- --------
PROPERTY:
Land 93,897 91,266 90,428
Buildings and leasehold improvements 387,475 356,205 361,635
Equipment and fixtures 316,730 286,033 287,675
Beverage licenses 7,511 7,384 7,468
---------- -------- --------
Total property--at cost 805,613 740,888 747,206
Less accumulated depreciation 337,996 309,889 312,112
---------- -------- --------
Property--net 467,617 430,999 435,094
---------- -------- --------
OTHER NON-CURRENT ASSETS 59,519 10,533 29,873
---------- -------- --------
TOTAL $1,024,200 $899,061 $946,289
---------- -------- --------
---------- -------- --------
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 197,854 $164,292 $170,855
Short-term borrowings 32,000 13,039 ---
Employee compensation and benefits 77,259 66,640 63,300
Taxes payable 31,687 30,512 46,079
Current portion of long-term debt and
guarantee of Profit Sharing Plan debt 3,351 3,319 3,210
Other 27,207 30,599 29,325
---------- -------- --------
Total current liabilities 369,358 308,401 312,769
---------- -------- --------
GUARANTEE OF PROFIT SHARING PLAN DEBT --- 2,677 1,803
LONG-TERM DEBT 13,682 --- 14,219
DEFERRED INCOME TAXES AND
OTHER LONG-TERM LIABILITIES 32,880 28,040 33,355
---------- -------- --------
STOCKHOLDERS' EQUITY:
Common stock (38,947,000, 38,767,000,
and 38,629,000 shares outstanding) 19,474 19,384 19,315
Additional capital 118,887 112,774 110,466
Common stock contribution to Profit Sharing Plan --- --- 9,856
Guarantee of Profit Sharing Plan debt (2,677) (5,996) (4,371)
Retained earnings 472,596 433,781 448,877
---------- -------- --------
Total stockholders' equity 608,280 559,943 584,143
---------- -------- --------
TOTAL $1,024,200 $899,061 $946,289
---------- -------- --------
---------- -------- --------
</TABLE>
See NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.
- 2 -
<PAGE>
STATEMENTS OF CONSOLIDATED CASH FLOWS (UNAUDITED)
<TABLE>
<CAPTION>
For the Three Quarters Ended
OCTOBER 29, October 30,
1998 1997
----------- -----------
---------(Thousands)--------
<S> <C> <C>
OPERATING ACTIVITIES:
Receipts from customers $ 2,347,045 $ 2,133,960
Payments for merchandise (1,721,434) (1,580,116)
Payments for operating and administrative expenses (511,339) (467,250)
Income tax payments (41,752) (28,365)
----------- -----------
Net cash provided by operating activities 72,520 58,229
----------- -----------
INVESTING ACTIVITIES:
Payments for property additions and other assets (115,872) (48,049)
Receipts from property dispositions 1,563 2,008
----------- -----------
Net cash used in investing activities (114,309) (46,041)
----------- -----------
FINANCING ACTIVITIES:
Dividend payments (16,330) (16,395)
Proceeds from short-term borrowings 32,000 13,039
Payments on long-term debt (537) ---
Repurchase of common stock --- (16,732)
Purchase of common stock from the Profit Sharing Plan (3,417) ---
----------- -----------
Net cash used in financing activities 11,716 (20,088)
----------- -----------
DECREASE IN CASH AND EQUIVALENTS (30,073) (7,900)
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD 48,552 22,834
----------- -----------
CASH AND EQUIVALENTS AT END OF PERIOD $ 18,479 $ 14,934
----------- -----------
----------- -----------
RECONCILIATION OF NET INCOME TO NET CASH
PROVIDED BY OPERATING ACTIVITIES:
Net income $ 40,024 $ 36,340
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 37,642 32,784
Deferred income taxes and other (3,126) (7,166)
Restricted stock awards 1,941 1,537
Common stock contribution to benefit plan 200 ---
Tax benefits credited to stockholders' equity 25 48
Changes in assets and liabilities:
Pharmacy and other receivables (833) (9,464)
Merchandise inventories (16,945) (4,696)
Other current assets 276 949
Current liabilities 13,316 7,897
----------- -----------
Net cash provided by operating activities $ 72,520 $ 58,229
----------- -----------
----------- -----------
</TABLE>
Non-cash investing and financing activities: In conjunction with the purchase
of Western Drug Distributors, Inc., the company assumed $11.2 million in
liabilities.
See NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.
- 3 -
<PAGE>
STATEMENTS OF CONSOLIDATED STOCKHOLDERS' EQUITY
For the Year Ended January 29, 1998 and Three Quarters Ended October 29, 1998
<TABLE>
<CAPTION>
COMMON STOCK
CONTRIBUTIONS GUARANTEE
COMMON STOCK TO PROFIT OF PROFIT TOTAL
------------------ ADDITIONAL SHARING SHARING RETAINED STOCKHOLDERS'
(Thousands) SHARES AMOUNT CAPITAL PLAN PLAN DEBT EARNINGS EQUITY
- ------------------------------------------------------------------------------------------------------------------------
BALANCE AT JANUARY 30, 1997 38,968 $19,484 $109,327 $9,955 ($7,555) $422,375 $553,586
- ------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
Net income 57,726 57,726
Dividends ($.56 PER SHARE) (21,808) (21,808)
Profit Sharing Plan:
Issuance of stock for FY97
contributions 375 188 9,767 (9,955) 0
Stock portion of FY98 contribution 9,856 9,856
Purchase of stock from plan (368) (184) (9,531) (9,715)
Reduction of plan debt 3,184 3,184
Restricted stock awards, net 88 44 2,021 2,065
Tax benefits related to employee
stock plans 61 61
Repurchase of common stock (434) (217) (1,118) (9,477) (10,812)
- ------------------------------------------------------------------------------------------------------------------------
BALANCE AT JANUARY 29, 1998 38,629 $19,315 $110,466 $9,856 ($4,371) $448,877 $584,143
- ------------------------------------------------------------------------------------------------------------------------
UNAUDITED:
Net income 40,024 40,024
Dividends ($.42 per share) (16,330) (16,330)
Profit Sharing Plan:
Issuance of stock for FY98
contributions 309 154 9,902 (9,856) 200
Purchase of stock from plan (105) (52) (3,365) (3,417)
Reduction of plan debt 1,694 1,694
Restricted stock awards, net 114 57 1,884 1,941
Tax benefits related to employee
stock plans 25 25
- ------------------------------------------------------------------------------------------------------------------------
BALANCE AT OCTOBER 29, 1998 38,947 $19,474 $118,887 $ 0 ($2,677) $472,596 $608,280
- ------------------------------------------------------------------------------------------------------------------------
</TABLE>
SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.
- 4 -
<PAGE>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. The Condensed Consolidated Financial Statements include Longs Drug Stores
Corporation (Company) and its wholly-owned subsidiary, Longs Drug Stores
California, Inc. All inter-company accounts and transactions have been
eliminated. The statements have been prepared on a basis consistent with
the accounting policies described in the Annual Report of the Company
previously filed with the Commission on Form 10-K for the year ended
January 29, 1998, and reflect all adjustments and eliminations which are,
in management's opinion, necessary for a fair statement of the results for
the periods. The Condensed Consolidated Financial Statements for the
periods ended October 29, 1998 and October 30, 1997 are unaudited. The
Consolidated Balance Sheet at January 29, 1998, and Consolidated Statement
of Stockholders' Equity for the year then ended, presented herein, have
been derived from the audited consolidated financial statements of the
Company included in the Form 10-K for the year ended January 29, 1998.
2. Certain reclassifications have been made to prior year financial
statements in order to conform to current financial statement
presentation.
3. The financial statements have been prepared using the Last-In-First-Out
(LIFO) method of accounting for inventories. The excess of specific
cost inventory over LIFO valuation was $144.5 million at October 29,
1998, $138.6 million at October 30, 1997, and $139.1 million at January
29, 1998. A final valuation of inventory under the LIFO method can be
made only after year-end based on ending inventory levels and inflation
rates for the year. Interim LIFO calculations are based on management's
estimates of year-end inventory levels and inflation rates for the year.
4. The Company has an unsecured revolving line of credit of $65 million and
drawdowns incur interest at prevailing rates. The agreement expires on
August 31, 2002. There was $32 million outstanding and $409,000
restricted for letters of credit as of October 29, 1998. The line of
credit contains quarterly and annual financial covenants which require
minimum tangible net worth and various financial ratios. The Company has
complied with restrictions and limitations included in the provisions of
the line of credit.
5. During the first quarter of fiscal year 1999, the Company repurchased
105,000 shares of common stock from the Profit Sharing Plan at market
values totaling $3.4 million. There were no repurchases of common stock
during the second and third quarters of fiscal year 1999. During the first
three quarters of fiscal year 1998, the Company repurchased 267,000 shares
of common stock from the Profit Sharing Plan at market values totaling $6.9
million and 399,000 common shares from the T. J. and V. M. Long Charitable
Foundations at market values totaling $9.8 million.
6. During July 1998, the Company completed its acquisition of Western Drug
Distributors, Inc. (Western). Western operated 20 Drug Emporium stores, 18
in Washington, mainly in the greater Seattle/Tacoma area, and 2 in the
Portland, Oregon area. The transaction was accounted for as a purchase and
results of operations for the former Western stores are included with those
of the Company since completion of the acquisition.
- 5 -
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
SALES
Third quarter sales increased 13.1% to $808.3 million and year-to-date sales
increased 9.5% to $2.35 billion. The Pacific Northwest acquisition of 20 stores
contributed $38.2 million of sales which was 4.7% of total third quarter sales
growth.
Total same store sales increased 7.8% for the quarter with pharmacy same store
sales increasing 17.4% and front-end (non-pharmacy) sales increasing 2.6%.
Pharmacy sales for the third quarter increased 23.2% and front-end sales
increased 9.6%. Increases in the number of prescriptions filled and in the
average prescription price are contributing to the increase in pharmacy
sales. Solid performances in core categories are leading the front-end sales
increases.
Year-to-date pharmacy sales are up 19.1% with front-end sales up 6.2%.
Year-to-date same store pharmacy sales are up 16.0% and year-to-date same
store front-end sales are up 2.4%.
Pharmacy represented 37.7% of total sales in third quarter, up from 34.6% in the
prior year. Pharmacy sales reimbursed through third party arrangements grew to
84.1% of total pharmacy sales compared to 82.5% in the prior year third quarter.
GROSS MARGINS
Gross margin as a percent of sales (including LIFO) was 26.45% for the third
quarter and 26.70% year-to-date. Improvements in front-end margins from
increases in sales of higher margin merchandise due to category management
initiatives were offset by inefficiencies related to the relocation of our
Northern California warehouse. Pharmacy margins as a percent of sales continue
to decline as claims reimbursed by third party (managed care) plans become a
larger portion of pharmacy sales and as pharmacy sales become a larger portion
of overall sales. However, total gross profit dollars were up 12.7%, closely
following the increase in sales of 13.1%.
A key measure of pharmacy profitability, gross profit dollars on a per script
basis, increased slightly. The downward trend in pharmacy margins and an upward
trend in average script price is expected to continue throughout the fiscal year
and into next year.
The Company uses the Last-In First-Out (LIFO) method of inventory valuation.
The LIFO provision was $200,000 for the third quarter compared to $2.9
million in the prior year quarter. This LIFO provision variance was a direct
result of the timing of manufacturer and vendor price increases as evident by
the year-to-date LIFO provision which was flat with last year at $5.4
million. The annualized inflation rate is expected to be 1.5% for the year.
OPERATING AND ADMINISTRATIVE EXPENSES
Operating and administrative expenses as a percent of sales for the third
quarter remained consistent with last year at 24.2%. Year-to-date operating
and administrative expenses as a percent of sales increased slightly from
23.7% last year to 23.9% this year. Included in operating and administrative
expenses are costs for the Year 2000 remediation effort. The effort is
proceeding according to plan, with $1.3 million expensed in the third quarter
and $3.4 million year-to-date, and is expected to be substantially complete
by the end of the year. The remaining expense for the fiscal year is
estimated to be $1 million.
- 6 -
<PAGE>
INCOME BEFORE TAXES/NET INCOME
Income before taxes as a percent of sales for the third quarter decreased to
2.2% compared to 2.3% in the prior year due to increased sales, strong front end
margins and control of operating expenses, offset by Year 2000 efforts. Net
income as a percent of sales remained consistent with prior year quarter at
1.4%.
The tax rate for the third quarter was 38.9% and 39.2% year-to-date. The
effective tax rate next year is expected to rise slightly to 40.5% as the profit
sharing plan debt will have been retired late this year and the tax deduction
for the dividends used to pay down that debt will no longer be available.
Net income for the three quarters increased 10.1% to $40.0 million. Diluted
earnings per share for the three quarters increased 10.6% to $1.03 per share
compared to $0.94 in the prior year.
LIQUIDITY AND CAPITAL RESOURCES
CASH POSITION
Cash provided by operating activities decreased compared to prior year due to
increased investment in inventory in new stores. Total store and warehouse
inventories, on a FIFO basis, increased $31.1 million from prior year. The bulk
of the $31.1 million inventory increase relates to the acquisition of 20 stores
in the Pacific Northwest ($24.8 million). Total warehouse inventories increased
$3.2 million. Average inventory per store at the end of the third quarter,
decreased by $25,000 compared to the same quarter prior year, mostly in the
pharmacy. Supply chain initiatives have reduced the days sales in store
pharmacy inventory from 30.7 days to 26.4 days.
Payments for property additions and other assets for the three quarters
increased $67.8 million compared to prior year primarily due to the acquisition
of 20 stores in the Pacific Northwest. Also included in capital expenditures is
the completion of a new warehouse that serves our stores in Northern California.
The number of stores in operation increased by 30, including the 20 stores from
the Pacific Northwest acquisition, from 345 to 375 since third quarter last
year. Capital expenditures for the year are expected to increase this year
primarily due to the Pacific Northwest acquisition, investment in new stores and
information systems.
At quarter end, there was $32.0 million outstanding on an unsecured revolving
line of credit at prevailing interest rates. The unused portion of the line of
credit was $33.0 million.
Expenditures for capital projects, dividends, and stock repurchases are expected
to continue to be funded from operations, cash reserves, and borrowings as
deemed necessary.
YEAR 2000 COMPLIANCE
Historically, computer systems have maintained two-digit year information in
date fields; for example, "98" has meant "1998." With the year 2000
approaching, some systems will be unable to process dates correctly. Processes
may abort or produce erroneous data. Systems that require the use of dates
beyond 1999 will run into this problem before 2000.
The problem can be found almost anywhere, in both hardware and software.
Mainframe systems, mid-range systems, and personal computers can all be a source
of trouble. So can elevators, point-of-sale systems, PBX's, and other devices
operating with embedded microcomputer chips that many people don't think of as
being "computers". If a company's systems cannot interpret the year 2000 dates
beyond 1999, some modification or replacement of the systems is necessary to
avoid system failures and the temporary inability to process transactions or
engage in the normal business activities.
In 1996 the Company established a Year 2000 Project Team, headed by the
Company's Chief Information Officer, to coordinate the Company's year 2000
efforts. The project team is staffed by the Company's
- 7 -
<PAGE>
Management Information Services personnel and outside consultants on an
as-needed basis. The Chief Information Officer reports regularly on the
status of year 2000 to the Company's senior officers and to the Company's
board of directors.
An assessment of the Company's MIS and non-MIS systems was completed to
determine which mission-critical systems were at risk, and a plan was developed
for replacing, refurbishing, or remediating both operating systems and business
applications to achieve year 2000 compliance. The implementation of the plan is
underway and the applications and operating systems are being modified or
replaced based on the level of priority. Management estimates all of the
activities with respect to assessment, clean-up, remediation, testing and
implementation are about 40% complete for MIS and about 30% complete for non-MIS
systems. The Company estimates that all critical systems and applications will
be year 2000 compliant by June 30, 1999.
The Year 2000 Project Team is also examining the Company's relationship with
certain key outside vendors and others with whom the Company has significant
business relationships to determine, to the extent practical, the degree of such
outside parties' year 2000 compliance. Although the Company is assessing the
year 2000 status of outside parties, there is no assurance that outside parties
will attain year 2000 compliance on a timely basis; if they do not, year 2000
problems could have a material impact on the Company's operations.
Management believes that should the Company or any third party with whom the
Company has a business relationship have a year 2000 related systems failure,
the most likely worst-case scenario would have to do with possible failure of
third party systems over which the company has no control, such as (but not
limited to) power and telecommunications, supply chain interruption, or
electronic commerce. Such an event could result in a substantial interruption
of business and have a material impact on the Company's results of operations.
Contingency planning is in process to provide for viable alternatives to ensure
that the Company's core business operations are able to continue in the event of
a year 2000 related systems failure. Management expects to have a comprehensive
contingency plan established by March 31, 1999.
In September 1998, at the request of the board of directors, an external
consulting group (IBM) conducted an independent review of the Company's year
2000 efforts. The Company's approach has been compared to IBM's Transformation
2000 methodology and their recommendations are being addressed. The Company
plans on performing additional external assessments in the future.
Through October 31, 1998, the Company has expended approximately $4.7 million to
address year 2000 compliance issues. The Company estimates that it will incur
an additional $2.6 million, for a total of approximately $7.3 million, to
address year 2000 compliance issues, which includes the estimated costs of all
modifications, testing and consulting fees.
The foregoing discussion of year 2000 compliance contains forward looking
statements about the Company's plans, expectations, costs, and consequences
regarding year 2000 matters. There can be no assurance that the Company's
expectations can be met and that the Company will not be adversely affected in a
way unidentified in the preceding discussion. Factors that could cause the
Company's results to differ from expectations include (but not limited to)
unforeseen problems, greater than anticipated costs, and unexpected difficulties
with outside parties.
FORWARD LOOKING INFORMATION
Certain information in this form 10-Q, as well as in other public filings, press
releases and oral statements made by our representatives, is forward-looking
information based on current expectations and plans that involve risks and
uncertainties. Forward-looking information includes statements concerning
pharmacy sales trends, prescriptions margins, number of store openings, the
level of capital expenditures and the company's success in addressing Year 2000
issues; as well as those that include or are preceded by the words "expects,"
"estimates," "believes" or similar language. For such statements, we claim the
protection
- 8 -
<PAGE>
of the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. The following factors, in addition to those discussed elsewhere in
this Form 10-Q and in our Annual Reports, could cause results to differ
materially from management expectations as projected in such forward-looking
statements: changes in economic conditions generally or in the markets served
by the company; consumer preferences and spending patterns; competition from
other drugstore chains, supermarkets, other retailers and mail order
companies; changes in state or federal legislation or regulations; the
efforts of third party payors to reduce prescription drug costs; the
availability and cost of real estate and construction; accounting policies
and practices; the company's ability to hire and retain pharmacists and other
store and management personnel; the company's relationships with its
suppliers; the ability of the company, its vendors and others to manage Year
2000 issues; the company's ability to successfully implement new computer
systems and technology; and adverse determinations with respect to litigation
or other claims. The company assumes no obligation to update its
forward-looking statements to reflect subsequent events or circumstances.
- 9 -
<PAGE>
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Reports on Form 8-K
There have been no reports on Form 8-K filed during the quarter
ended October 29, 1998.
- 10 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
LONGS DRUG STORES CORPORATION
-----------------------------------------
(REGISTRANT)
Date December 11, 1998 /s/ G. L. White
--------------------- -----------------------------------------
G. L. White
Vice President, Controller
/s/ R. A. Plomgren
-----------------------------------------
R. A. Plomgren
Senior Vice President, Development
and Chief Financial Officer and Director
- 11 -
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JAN-28-1999
<PERIOD-START> JAN-30-1998
<PERIOD-END> OCT-29-1998
<CASH> 18,479
<SECURITIES> 0
<RECEIVABLES> 64,063
<ALLOWANCES> 0
<INVENTORY> 386,796
<CURRENT-ASSETS> 497,064
<PP&E> 805,613
<DEPRECIATION> 337,996
<TOTAL-ASSETS> 1,024,200
<CURRENT-LIABILITIES> 369,358
<BONDS> 0
0
0
<COMMON> 19,474
<OTHER-SE> 588,806
<TOTAL-LIABILITY-AND-EQUITY> 1,024,200
<SALES> 2,347,879
<TOTAL-REVENUES> 0
<CGS> 1,721,053
<TOTAL-COSTS> 2,282,055
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 532
<INCOME-PRETAX> 65,824
<INCOME-TAX> 25,800
<INCOME-CONTINUING> 40,024
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 0
<EPS-PRIMARY> 1.04
<EPS-DILUTED> 1.03
</TABLE>
